MELVILLE, N.Y., May 16, 2017 /PRNewswire/ -- Canon BioMedical is pleased to announce the launch of our Novallele genotyping products in Canada for sale through our distributor, Cedarlane Corporation. The Novallele portfolio covers genetic variations that can be difficult to genotype and offers a targeted approach for research laboratories to quickly obtain genotyping answers in their investigations. Using the Novallele control sets, researchers can easily and quickly verify their genotyping calls.
"While attending conferences and tradeshows in Canada, we recognized the need to offer a complete genotyping solution to researchers in Canada," states Dennis Snyder, Senior Director of Global Commercial Operations for Canon BioMedical. "We look forward to working with Cedarlane, an experienced and reputable distributor in Canada, to expand the availability of our Novallele assays."
Since launching our first Novallele genotyping products in September of 2015, Canon BioMedical has expanded the assay menu to include numerous targets. The assays provide unique solutions for mitochondrial DNA and large deletions while supporting a variety of research areas, such as pharmacogenetics, cancer, and inherited disease. With the launch of Novallele Control Sets in late 2016, Canon BioMedical ensured researchers can genotype a single sample with confidence. The full menu of 351 genotyping assays, complementary chemistry reagents, and control sets are now available in Canada.
The Novallele genotyping assays detect genetic variations using polymerase chain reaction (PCR) followed by high-resolution melting (HRM) analysis on any thermocycler capable of HRM. In addition to a large number of SNP targets, there are also assays for genotyping small and large insertions and deletions.
The Novallele genotyping assays, reagents, and control sets are now available for purchase in Canada through Cedarlane at www.cedarlanelabs.com. Canon BioMedical will exhibit at the 7th Annual Cedarlane Life Science & Medical Lab Expo on May 25th in Toronto, Canada. Our customers in the United States should continue to visit www.canon-biomedical.com for ordering and purchasing information.
About Cedarlane
Established in 1957, Cedarlane has grown within the life science industry to become a multi-national corporation with over 100 employees in Canada and the United States. The two main locations are in Burlington, Ontario, Canada, and Burlington, North Carolina, USA. Cedarlane Corporation and its many divisions are privately held entities, all of which are owned and operated by the same two shareholders who have remained unchanged since 1984. Employees work closely with both customers and suppliers to offer a personalized and comprehensive experience to reflect the core value that customers are of the utmost importance.
About Canon BioMedical
Canon BioMedical, a wholly owned subsidiary of Canon U.S.A., Inc., is focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing innovative technologies and solutions. The technologies and solutions developed will help enable clinicians and scientists to improve our health and advance science. Canon BioMedical will continue to pursue innovative solutions in line with Canon's Kyosei philosophy of social and environmental responsibility through the use of existing and emerging Canon technology as well as strategic partnerships.
Products mentioned in this release are for Research Use Only. Not for use in diagnostic procedures.
All referenced product names, and other marks, are trademarks of their respective owners. © 2017 Canon BioMedical, Inc. All rights reserved.
Advertisement
"While attending conferences and tradeshows in Canada, we recognized the need to offer a complete genotyping solution to researchers in Canada," states Dennis Snyder, Senior Director of Global Commercial Operations for Canon BioMedical. "We look forward to working with Cedarlane, an experienced and reputable distributor in Canada, to expand the availability of our Novallele assays."
Advertisement
Since launching our first Novallele genotyping products in September of 2015, Canon BioMedical has expanded the assay menu to include numerous targets. The assays provide unique solutions for mitochondrial DNA and large deletions while supporting a variety of research areas, such as pharmacogenetics, cancer, and inherited disease. With the launch of Novallele Control Sets in late 2016, Canon BioMedical ensured researchers can genotype a single sample with confidence. The full menu of 351 genotyping assays, complementary chemistry reagents, and control sets are now available in Canada.
The Novallele genotyping assays detect genetic variations using polymerase chain reaction (PCR) followed by high-resolution melting (HRM) analysis on any thermocycler capable of HRM. In addition to a large number of SNP targets, there are also assays for genotyping small and large insertions and deletions.
The Novallele genotyping assays, reagents, and control sets are now available for purchase in Canada through Cedarlane at www.cedarlanelabs.com. Canon BioMedical will exhibit at the 7th Annual Cedarlane Life Science & Medical Lab Expo on May 25th in Toronto, Canada. Our customers in the United States should continue to visit www.canon-biomedical.com for ordering and purchasing information.
About Cedarlane
Established in 1957, Cedarlane has grown within the life science industry to become a multi-national corporation with over 100 employees in Canada and the United States. The two main locations are in Burlington, Ontario, Canada, and Burlington, North Carolina, USA. Cedarlane Corporation and its many divisions are privately held entities, all of which are owned and operated by the same two shareholders who have remained unchanged since 1984. Employees work closely with both customers and suppliers to offer a personalized and comprehensive experience to reflect the core value that customers are of the utmost importance.
About Canon BioMedical
Canon BioMedical, a wholly owned subsidiary of Canon U.S.A., Inc., is focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing innovative technologies and solutions. The technologies and solutions developed will help enable clinicians and scientists to improve our health and advance science. Canon BioMedical will continue to pursue innovative solutions in line with Canon's Kyosei philosophy of social and environmental responsibility through the use of existing and emerging Canon technology as well as strategic partnerships.
Products mentioned in this release are for Research Use Only. Not for use in diagnostic procedures.
All referenced product names, and other marks, are trademarks of their respective owners. © 2017 Canon BioMedical, Inc. All rights reserved.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/canon-biomedical-products-now-available-in-canada-300458395.html
SOURCE Canon BioMedical
